Phase 4 Osteoarthritis Trial, Recruiting NCT05806021 Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Condition: Osteoarthritis
Back to Osteoarthritis

Phase 4 Osteoarthritis Trial, Recruiting

NCT05806021
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been experiencing pain or symptoms in one knee for more than 6 months, diagnosed as knee osteoarthritis according to standard medical guidelines
  • Your knee osteoarthritis has been graded as mild to moderate (Grade 1 to 3) on a standard X-ray scoring system
  • Your knee pain during activity rates higher than 4 but lower than 8 out of 10 on a pain scale

Who may not be able to join:

  • You have painful osteoarthritis in both knees at the same time
  • Your knee osteoarthritis is severe (Grade 4 on the standard X-ray scoring system)
  • Your osteoarthritis only affects the kneecap area of the joint, not the main part of the knee
  • You have received a cortisone (steroid) injection into the knee in the past 3 months, or you regularly take steroid tablets by mouth
  • You have received a hyaluronic acid injection into the knee in the past 12 months
  • You have received a platelet-rich plasma (PRP) injection into the knee in the past 12 months
  • You have another condition affecting the knee joint, such as a inflammatory disease, a history of joint infection, or bone damage (confirm with trial site)
  • There are signs or suspicion of an active infection near or in the knee
  • There are signs or suspicion of a tumour or cancer spread near the knee
  • You have had a serious knee injury in the last 3 months
  • You have significant memory or thinking difficulties, or difficulty understanding the study language well enough to complete questionnaires
  • You have another serious health condition that could prevent you from participating or that makes cortisone injections unsafe for you (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Dien Hung Luong, MD, Centre hospitalier de l'Université de Montréal (CHUM)

Phone: 5148908000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Registry
ClinicalTrials.gov
Start date
15 January 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

WOMAC Function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov